Emergent BioSolutions director logs sales, new grants
Emergent BioSolutions director Donald W. DeGolyer reported both equity grants and tax-related share sales.
Rhea-AI Filing Summary
Emergent BioSolutions director Donald W. DeGolyer reported both equity grants and tax-related share sales. On April 30, he received 25,344 restricted stock units as an annual board grant and 11,296 stock options with a $7.99 exercise price, both vesting one year after grant if he remains on the board.
In connection with RSUs that vested on April 29, he sold a total of 15,481 common shares in open-market transactions on May 1 under a pre-arranged Rule 10b5-1 trading plan to satisfy tax obligations. Following these sales, he directly holds 129,721 common shares, along with the newly granted unvested options.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 15,481 shares
Net Sell
4 txns
Insider
DeGolyer Donald W
Role
Director
Sold
15,481 shs ($130K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 14,527 | $8.36 | $121K |
| Sale | Common Stock | 954 | $8.96 | $9K |
| Grant/Award | Stock Option (Right to Buy) | 11,296 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 25,344 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 11,296 contracts (Direct);
Common Stock — 129,721 shares (Direct)
Footnotes (6)
- F1. Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.
- F2. Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated August 11, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026.
- F3. The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $7.78 to $8.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F4. The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $8.80 to $8.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F5. Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.
- F6. The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.
Key Figures
Shares sold: 15,481 shares
Sale price (first block): $8.36/share
Sale price (second block): $8.96/share
+4 more
7 metrics
Shares sold
15,481 shares
Open-market sales on May 1, 2026
Sale price (first block)
$8.36/share
Weighted average; trades from $7.78 to $8.64
Sale price (second block)
$8.96/share
Weighted average; trades from $8.80 to $8.99
RSUs granted
25,344 units
Annual grant for board and committee service on Apr. 30, 2026
Stock options granted
11,296 options
Annual grant on Apr. 30, 2026, for board service
Option exercise price
$7.99/share
Exercise price for 11,296 stock options expiring Apr. 30, 2033
Shares held after transactions
129,721 shares
Direct common stock holdings after May 1, 2026 sales
Key Terms
restricted stock units ("RSUs"), Rule 10b5-1 trading plan, Stock Incentive Plan, weighted average price, +1 more
5 terms
restricted stock units ("RSUs") financial
"Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Rule 10b5-1 trading plan regulatory
"Shares were sold pursuant to a Rule 10b5-1 trading plan, dated August 11, 2025"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Incentive Plan financial
"granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service"
A stock incentive plan is a company program that gives employees or directors pieces of ownership or the right to buy shares over time, similar to receiving a bonus paid in company stock instead of cash. Investors pay attention because these plans align staff incentives with long‑term company performance but can also dilute existing shareholders and affect reported profits when grants are expensed, so they influence both ownership percentages and financial results.
weighted average price financial
"The price reported in Column 4 is a weighted average price for sales executed on the same day"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Black-Scholes value financial
"dividing by the Black-Scholes value of a single option calculated as of the date of the grant"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Emergent BioSolutions (EBS) director Donald DeGolyer do in this Form 4 filing?
Donald W. DeGolyer reported routine board-related equity activity. He received new RSU and stock option grants, and sold shares in open-market trades under a Rule 10b5-1 plan to cover tax obligations tied to recently vested restricted stock units.
What equity grants did Donald DeGolyer receive from Emergent BioSolutions (EBS)?
He received 25,344 restricted stock units and 11,296 stock options as part of annual non-employee director compensation. Each RSU and option relates to one common share, with the options carrying a $7.99 exercise price and vesting one year after the grant date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
